Anika Therapeutics (ANIK) Tops Q1 EPS by 17c

April 27, 2016 4:06 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of $0.45, $0.17 better than the analyst estimate of $0.28. Revenue for the quarter came in at $22.3 million versus the consensus estimate of $19.26 million.

“We are off to a strong start in 2016, with total revenue growth of 44% year-over-year for the first quarter and advancement of our long-term growth strategy,” said Charles H. Sherwood, Ph.D., President and Chief Executive Officer. “We received CE Mark approval for CINGAL and continued to strengthen our infrastructure to support future growth. We also commenced our $25 million accelerated share repurchase program, reflecting our confidence in the business and deep commitment to creating shareholder value. We were pleased to continue our solid momentum in the first quarter, and we remain focused on positioning Anika for sustained growth.”

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Hot Earnings, Management Changes

Related Entities